Topical Ruxolitinib Therapeutic Cheat Sheet
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT …
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … Continue reading "Topical Ruxolitinib Therapeutic Cheat Sheet"
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Amit Pandya, staff dermatologist with Palo Alto Foundation Medical Group and adjunct professor in the department of dermatology at the University of Texas Southwestern Medical Center. Dr. Pandya says this is the most exciting time for him as a dermatologist with new vitiligo medications on the market an … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange (PDE) Symposium interviewed Dr. Arielle Kauvar, clinical professor of dermatology at NYU Grossman School of Medicine. Learn the unique role lasers can play in treating melasma and post-inflammatory hyperpigmentation, especially when patients don’t respond to conventional therapy. Hear from the expert on what lasers to use when … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium (PDE) interviewed Dr. Jennifer Rullan, a dermatologist in Chula Vista, Calif. Watch as Dr. Rullan outlines unexpected ingredients that dermatologists can use in medium depth and deep chemical peels to treat pigmentary disorders, and it may not be the disorders that you expect. Vitiligo? Idiopathic guttate hypomelanosis … 
At the 2023 ODAC Dermatology, Aesthetic & Surgical Conference, we were lucky to learn about the management of vitiligo from the renowned researcher and clinician, Dr. John Harris, Professor and Chair of Dermatology at the University of Massachusetts. When a new patient with vitiligo presents to my clinic, I always pull out my phone to consult Dr. Harris’ treatment protocol – I am sure I … 